Skip to main navigation menu Skip to main content Skip to site footer
FrancoAngeli Journals

Newsletter "Clinica dell'Alcolismo"

No. 46 (2016)

La terapia farmacologia dell’alcolismo: il sodio oxibato (acido gamma-idrossibutirrico- GHB) farmaco anti-alcol approvato dall’organismo regolatorio italiano per la pratica clinica. Parte III

Submitted
aprile 21, 2017
Published
2017-04-21

References

  1. Addolorato G., Castelli E., Stefanini G.F., Casella G., Caputo F., Marsigli L., Bernardi M., Gasbarrini G. (1996), “An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects”, Alcohol and Alcoholism, 31: 341-345.
  2. Addolorato G., Cibin M., Caputo F., Capristo E., Gessa G.L., Stefanini G.F., Gasbarrini G. (1998), “γ-Hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients”, Drug and Alcohol Dependence, 53: 7-10.
  3. Addolorato G., Balducci G., Capristo E., Attilia M.L., Taggi F., Gasbarrini G., Ceccanti M. (1999), “Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine”, Alcoholism: Clinical and Experimental Research, 23: 1596-1604.
  4. Addolorato G., Caputo F., Capristo E, Stefanini G.F., Gasbarrini G. (2000), “Gamma-hydroxybutyric acid: efficacy, potential abuse, and dependance in the treatment of alcohol addiction”, Alcoholism, 20: 217-222.
  5. Addolorato G., Leggio L., Abenavoli L., Gasbarrini G., Alcoholism Treatment Study Group (2005a), “Neurobiochemical and clinical aspects of craving in alcohol addiction: a review”, Additive Behaviors, 30: 1209-1224.
  6. Addolorato G., Abenavoli L., Leggio L., Gasbarrini G. (2005b), “How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review”, Neuropsychobiology, 51: 59-66.
  7. Addolorato G., Leggio L., Ferrulli A., Caputo F., Gasbarrini A. (2009), “The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data”, Expert Opinion on Investigational Drugs, 18: 675-686.
  8. Addolorato G., Leggio L., Ferrulli A., Cardone S., Bedogni G., Cpauto F., Gasbarrini G., Landolfi R., Baclofen Study Group (2011), “Doseresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial”, Alcohol and Alcohoism, 46: 312-317.
  9. Aldrete J.A., Barnes D.P. (1968), “4-Hydroxybutyrate anaesthesia for cardiovascular surgery. A comparison with halothane”, Anaesthesia, 23: 558-565.
  10. American Psychiatric Association (APA) (1988), Manuale Diagnostico e Statistico dei Disturbi Mentali 3a Ed. Rev. (DSM-III-R, American Psychiatric Press, Washington DC, 1987), Masson, Milano.
  11. American Psychiatric Association (APA) (1996), Manuale Diagnostico e Statistico dei Disturbi Mentali 4a Ed. (DSM-IV, American Psychiatric Press, Washington DC, 1994), Masson, Milano.
  12. American Psychiatric Association (APA) (2001), Manuale Diagnostico e
  13. Statistico dei Disturbi Mentali 4a Ed. TR. (DSM-IV-TR American Psychiatric Press, Washington DC, 2000), Masson, Milano.
  14. American Psychiatric Association (APA) (2014), Manuale Diagnostico e
  15. Statistico dei Disturbi Mentali Quinta Edizione (DSM-5 American Psychiatric Publishing, Arlington, 2013), Raffaello Cortina, Milano.
  16. Andriamampandry C., Taleb O., Viry S., Muller C., Humbert J.P., Gobaille S., Aunis D., Maitre M. (2003), “Cloning and chracterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB)”, FASEB Journal, 17: 1691-1693.
  17. Andriamampandry C., Taleb O., Kemmel V., Humbert J.P., Aunis D., Maitre M. (2007), “Cloning and chracterization of a gammahydroxybutyrate receptor identified in the human brain”, FASEB Journal, 21: 885-895.
  18. Anton R.F., Mohak D.H., Lathan P. (1995), “The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior”, Alcoholism: Clinical and Experimental Research, 19: 92-99.
  19. Beghè F., Carpanini M.T. (2000), “Safety and tolerability of gammahydroxybutyric acid in the treatment of alcohol-dependent patients”,
  20. Alcoholism, 20: 223-225.
  21. Benarroch E.E. (2009), “γ-Hydroxybutyric acid and its relevance in neurology”, Neurology, 72: 282-286.
  22. Benavides J., Rumigny J.F., Bourguignon J.J., Cash C., Wermuth C.G., Mandel P., Vincendon G., Maitre M. (1982), “High affinity binding sites for gamma-hydroxybutyric acid in rat brain”, Life Sciences, 30: 953-961.
  23. Bessmann S.P., Fishbein W.M. (1963), “Gamma-hydroxybutyric, a normal brain metabolite”, Nature, 200: 1207-1208.
  24. Brambilla R., Vigna-Taglianti F., Avanzi C., Faggiano F., Leone M. (2012), “Il gamma-idrossibutirrato (GHB) nel trattamento a medio/lungo termine della dipendenza da alcol: una revisione sistematica”, Rivista di Psichiatria, 47: 269-280.
  25. Broughton R., Mamelak M. (1980), “Effects of noctural gammahydroxybutyrate
  26. on sleep/waking patterns in nacolepsy-cataplexy”, Canadian Journal of Neurological Sciences, 7: 23-31.
  27. Cacciaglia R., Lesch O.M., Vivet P. (2013) “GATE 2 study: sodium oxybate in the maintenance of alcohol abstinence and prevention of alcohol relapse [abstract no. P30]”, Acohol and Alcoholism, 48, S1: i47-48, plus poster presented at the 14th Congress of the European Society for Biomedical Research on Alcoholism, Warsaw, 8-11 September.
  28. Canton G., Ferri M., Forza G., Brambilla C., Minazzato L., Gallimberti L. (1991), Un questionario per la valutazione del craving alcolico: l’ACS (Alcohol Craving Scale), 1° Congresso Nazionale SITD, Roma 25-27 novembre.
  29. Caputo F. (2011), “Le prospettive future della terapia farmacologia per l’alcolismo”, Mission, 32: 18-24.
  30. Caputo F., Addolorato G., Lorenzini F., Domenicali M., Greco G., Del Re A., Gasbarrini G., Stefanini G.F., Bernardi M. (2003), “Gammahydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study”, Drug and Alcohol Dependance, 70: 85-91.
  31. Caputo F., Addolorato G., Trevisani F., Bernardi M. (2005a), “γ-Hydroxybutyrate as a treatment for alcoholism”, Lancet, 366: 981-982.
  32. Caputo F., Vignoli T., Lorenzini F., Ciuffoli E., Del Re A., Stefanini G.F., Addolorato G., Trevisani F., Bernardi M.; Alcoholism Treatment Study Group (2005b), “Suppression of craving for gammahydroxybutyric acid by naltrexone administration: three case reports”, Clinical Neuropharmacology, 28: 87-89.
  33. Caputo F., Addolorato G., Stoppo M., Francini S., Vignoli T., Lorenzini F., Del Re A., Comaschi C., Androne P., Trevisani F., Bernardi M. (2007), “Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study”, European
  34. Neuropsychopharmacology, 17: 781-789.
  35. Caputo F., Vignoli T., Maremmani I., Bernardi M., Zoli G. (2009), “Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependance: A review”, International Journal of Environmental Research and Public Health, 6: 917-1929.
  36. Caputo F., Francini S., Brambilla R., Vigna-Taglianti F., Stoppo M., Del Re A., Leggio L., Addolorato G., Zoli G., Bernardi M. (2011), “Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity”, European Neuropsychopharmacology, 21: 450-456.
  37. Caputo F., Skala K., Walter H., Ceccanti M., Djurkowski M., Filipecka E., Florkowski A., Gerra G., Holzbach R., Horodnicki J., Platz W., Spazzapan B., Zblowska H., Bernardi M., Cacciaglia R., Vivet P., Lesch O.M., Addolorato G. (2013), “Sodium oxibate in the prevention of alcohol relapses in alcohol dependent patients (GATE 2 Study)”, Alcohol and Alcoholism, 48: S1-i33.
  38. Caputo F., Skala K., Mirijello A., Ferulli A., Walter H., Lesch O., Addolorato G. (2014a), “Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial”, CNS Drugs, 28: 743-752.
  39. Caputo F., Del Re A., Brambilla R., Grignaschi A., Vignoli T., Vigna-Taglianti F., Addolorato G., Zoli G., Cibin M., Bernardi M. (2014b), “Sodium oxybate in maintaining alcohol abstinence in alcoholic patients according to Lesch typology: a pilot study”, Journal of Psychopharmacology, 28: 23-30.
  40. Caputo F., Mirijello A., Cibin M., Mosti A., Ceccanti M., Domenicali M., Bernardi M., Maremmani I., Addolorato G., for the “Twentieth Anniversary of the Use of SMO in Italy” Group” (2015), “Novel strategies to treat alcohol dependence with sodium oxybate according to clinical practice”, European Review for Medical and Pharmacological Sciences, 19: 1315-1320.
  41. Carter L.P., Koek W., France C.P. (2009), “Behavioural analyses of GHB: receptor mechanisms”, Pharmacology and Therapeutics, 121: 100-114.
  42. Chick J., Nutt D.J. (2012), “Substitution therapy for alcoholism: time for a reappraisal?”, Journal of Psychopharmacology, 26: 205-212.
  43. Cibin M., Nava F. (2011) “Psicobiologia del craving”, in Hinnenthal I.M., Cibin M. (a cura di), Il trattamento residenziale breve delle dipendenze da alcol e da cocaina. Il modello Soranzo, SEEd, Torino: 65-81.
  44. Cibin M., Danieli D., Levarta E., Suardi L. (2010), “Alcover nella clinica dell’alcolismo: i risultati del questionario alla luce dei dati di letteratura”, in Ceccanti M., Maremmani I., Cibin M., Mosti A. (a cura di), Craving nell’alcolista: ricerca-riflessioni, osservazioni cliniche-terapia, CLUEB, Bologna: 55-67.
  45. Cibin M., Caputo F., Addolorato G., Bernardi M. (2013), “Il gamma idrossibutirrato (GHB) nella ricerca e nella pratica clinica: efficacia e potenzialità d’abuso”, Mission, 38: 40-46.
  46. Cloninger C.R. (1987), Tridimensional Personality Inventory Questionnaire (TPQ), version 4, Washington University Medical School, Department of Psychiatry, St Louis.
  47. Cloninger C.R., Sigvardson S., Gilligan S.B., von Knorring A.L., Reich T., Bohman M. (1988), “Genetic heterogeneity and the classification of alcoholism”, Advances in Alcohol and Substance Abuse, 7: 3-16.
  48. Dauvilliers Y., Arnulf I., Mignot E. (2007), “Narcolepsy with cataplexy”, Lancet, 369: 499-511.
  49. Di Bello M.G., Gambassi F., Mugnai L., Masini E., Mannaioni P.F. (1995), “Gamma-hydroxybutyric acid induced suppression and prevention of alcohol withdrawal syndrome and relief of craving in alcohol dependent patients”, Alcologia, 7: 9-16.
  50. European Medicine Agency (2010) Guideline on the development of medicinal products for the treatment of alcohol dependence, w w w. e m a . e u r o p a . e u / d o c s / e n _ G B / d o c u m e n t _library/Scientific_guideline/2010/03/WC500074898.pdf.
  51. Gallimberti L., Gentile N., Cibin M., Fadda F., Canton G., Ferri M., Ferrara S.D., Gessa G.L. (1989), “Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome”, Lancet, 2: 787-789.
  52. Gallimberti L., Ferri M., Ferrara S.D., Fadda F., Gessa G.L. (1992), “Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study”, Alcoholism: Clinical and Experimental Research, 16: 673-676.
  53. Garbolino S., Rosso C., Tartaglia R., Pini D., Lapio D., Natta P., Vaccaro A., Faro G. (2007), “Disturbo da uso di sostanze e comorbilità psichiatrica: esperienza con olanzapina”, Mission, 22: 19-24.
  54. Guy W. (1976), Clinical Global Impressions in ECDEU Assessment Manual for Psycopharmacology, Revised, Psycopharmacology Research Branch, National Institute of Health, Rockville: 217-222.
  55. Keating G.M. (2014), “Sodium oxybate: A review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence”, Clinical Drug Investigation, 34: 63-80.
  56. Kleinschmidt S., Grundmann U., Knocke T., Silomon M., Bach F., Larsen R. (1998), “Total intravenous anaesthesia with gammahydroxybutyrate (GHB) and sufentanil in patients undergoing
  57. coronary artery bypass graft surgery: a comparison in patients with unimpaired and impaired left ventricular function”, European Journal of Anaesthesiology, 15: 559-564.
  58. Koek W., France C.P. (2008), “Cataleptic effects of gamma-hydroxybutyrate (GHB) and baclofen in mice: mediation by GABA(B) receptors, but differential enhancement by N-methyl-d-aspartate (NMDA) receptor antagonist”, Psychopharmacology, 1999: 191-198.
  59. Korninger C., Roller R.E., Lesch O.M. (2003), “Gamma-hydroxybutyric acid in the treatment of alcohol withdrawal syndrome in patients admitted to hospital”, Acta Medica Austriaca, 30: 83-86.
  60. Laborit H., Jouany J.M., Gerard J., Fabiani F. (1960), “Summary of an experimental and clinical study on a metabolic substrate with inibitory central action: sodium 4-hydroxybutyrate”, Presse Medicale, 68: 1867-1869.
  61. Leggio L., Abenavoli L., Caputo F., Gasbarrini G., Addolorato G. (2005), “Il craving da alcol: tipologia, aspetti clinici e metodi di misurazione”, in Trevisani F., Caputo F. (a cura di), Alcolismo, CLUEB, Bologna: 69-74.
  62. Leonardi C., Nava F. (2007), “Uso del gamma-idrossibutirrato (GHB) e della buprenorfina nel paziente politossicodipendente”, Mission, 23: 27-32.
  63. Leone M.A., Vigna-Taglianti F., Avanzi G., Brambilla R., Faggiano F. (2010), “Gamma-hydroxybutyrate (GHB) for the treatment of alcohol withdrawal and prevention relapses”, Cochrane Database Systematic Reviews, 2: CD006266.
  64. Lesch O.M., Walter H. (1996), “Subtypes of alcoholism and their role in therapy”, Alcohol and Alcoholism, 31: 63-67.
  65. Lesch O.M., Dietzel M., Musalek M., Walter H., Zeiler K. (1988), “The course of alcoholism. Long-term prognosis in different types”, Forensic Science International, 36: 121-138.
  66. Lesch O.M., Walter H., Bonte W., Gruenberger M., Musalek M., Sprung R. (1991), “Chronic alcoholism: subtypes useful for therapy and research”, in Palmer T.N. (ed.), Alcoholism: a molecular perspective. Nato Asi Series A: Life Sciences, Vol. 206, Plenum Press, New York: 353-356.
  67. Mamelak M., Escrui J.M., Stokan O. (1977), “The effects of γ-hydroxybutyrate on sleep”, Biological Psychiatry, 12: 273-278.
  68. Mamelak M., Scharf M.B., Woods M. (1986), “Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings”, Sleep, 9: 285-289.
  69. Manzato E., Nava F., Biasin C., Faccini M., Cifelli G. (2006a), “Gli esami di laboratorio nell’assessment dei disturbi correlati a sostanze psicoattive in soggetti con comorbilità psichiatrica”, Mission, 20: 19-34.
  70. Manzato E., Biasin C., Nava F. (2006b), “La diagnosi nei disturbi da uso di sostanze psicoattive e nella comorbilità psichiatrica associata”, Mission, 17: 21-30.
  71. Manzato E., Nava F., Borroni G., Bosticco E., Bravin S., Fertonani Affini G., Gasparini G., Richini M., Thoux M., Torriani M., Lucchini A. (2016), “L’efficacia, la sicurezza e la maneggevolezza del sodio oxibato: i risultati dello studio GUM (CHB-Use and Misuse)”, Mission, in press.
  72. Maremmani I., Pacini M. (2005), “L’uso del gamma-idrossibutirrato di sodio (GHB) negli eroinomani alcolisti”, Heroin Addiction and Related Clinical Problems, 7, suppl.: S3-S23.
  73. Maremmani I., Pacini M. (2007), “Use of sodium gammahydroxybutyrate in alcoholic heroin addicts and polydrug-abusers”, Heroin Addiction and Related Clinical Problems, 9: 55-76.
  74. Maremmani I., Lamanna F., Tagliamone A. (2001a), “Long-term therapy using GHB (sodium gamma hydroxybutyrate) for treatment-resistant chronic alcoholics”, Journal of Psychoactive Drugs, 33: 135-142.
  75. Maremmani I., Canoniero S., Pacini M., Guareschi R. (2001b), “Alcol e disturbo mentale: principi di trattamento”, in Cibin M., Mazzi M., Rampazzo L., Serpelloni G. (a cura di), L’alcologia nell’ambulatorio del medico di medicina generale, Leardini, Venezia: 371-383.
  76. Maremmani I., Canoniero S., Pacini M. (2001c), “Clinica e terapia dei disturbi da uso di alcol. Farmaci che riducono l’uso di alcol, cocaina ed oppiacei”, in Maremmani I. (a cura di), Manuale di neuropsicofarmacologia, psichiatrica e dell’abuso di sostanze, Pacini, Pisa: 133-154.
  77. Maremmani I., Cibin M., Mosti A., Ceccanti M. (2010), “GHB nella clinica dell’alcolismo: raccomandazioni e osservazioni”, Medicina delle Tossicodipendenze, 67: 51-59.
  78. Maremmani A.G.I., Pani P.P., Rovai L., Pacini M., Dell’Osso L., Maremmani I. (2011), “Long-term γ-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics”, International Journal of Environmental Research and Public Health, 8: 2816-2827.
  79. Martinotti G., Di Nicola M., Tedeschi D., Collea A., Mieli G., Guglielmo R., Fiorentino R., De Risio L., Harnic D., De Vita O., Hatzigiakoumis D.S., Ruggeri F.M., Romanelli R., Gualtieri I., Aliotta F., Quatrale M., Di Giannantonio M., Janiri L. (2012), “Una scala di valutazione delle tipologie di craving: il Craving Typology Questionnaire (CTQ)”, Dipendenze Patologiche, 7: 21-26.
  80. Moncini M., Masini E., Gambassi F., Mannaioni P.F. (2000), Gammahydroxybutyric
  81. acid and alcohol-related syndromes”, Alcohol, 20: 285-291.
  82. Nava F. (2004) Manuale di neurobiologia e clinica delle dipendenze, FrancoAngeli, Milano.
  83. Nava F. (2006), “L’uso del GHB negli eroinomani alcolisti: aspetti critici e possibili modalità d’uso”, Heroin Addiction and Related Clinical Problems, 8: 1-10.
  84. Nava F. (2010), “La doppia diagnosi e l’integrazione dei trattameni fra criticità organizzative e gestionali: l’esperienza della Regione Veneto”, in Lucchini A., Strepparola G. (a cura di), Modelli di intervento in alcologia. L’esperienza e le indicazioni operative condivise dagli operatori pubblici e privati in Lombardia, FrancoAngeli, Milano: 98-105.
  85. Nava F., Manzato E. (2015), “Il trattamento farmacologico dell’alcolismo”, in Manzato E., Nava F. (a cura di), Il craving dell’alcolista: Neurobiologia, psicopatologia e pratica clinica. Trattamento alcologico, psichiatrico e dei disturbi d’ansia, Vol. 2, FrancoAngeli, Milano, in press.
  86. Nava F., Premi S., Manzato E., Lucchini A. (2006), “Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptions”, Journal of Psychoactive Drugs, 38: 211-217.
  87. Nava F., Premi S., Manzato E., Campagnola W., Lucchini A., Gessa G.L. (2007), “Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam”, American Journal of Drug and Alcohol Abuse, 33: 379-392.
  88. Nava F., Vendramin A., Manzato E., Cibin M., Lucchini A. (2010), “New frontiers in alcoholism and addiction treatment”, Recent Patents on CNS Drug Discovery, 5: 81-94.
  89. Nava F., Bravin S., Borroni G., Bosticco E., Fertonani Affini G., Gasparini G.L., Manzato E., Thoux M., Torriani M., Richini M., Lucchini A. (2013), “A retrospective study on the use of sodium oxybate in northen Italy [abstract no. SAT2.4]”, Acohol and Alcoholism, 48, Suppl. 1: i34.
  90. Nimmerrichter A.A., Walter H., Gutierrez-Lobos K.E., Lesch O.M. (2002), “Double-blind controlled trial of Á-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal“, Alcohol and Alcoholism, 37: 67-73.
  91. Palatini P., Tedeschi L., Frison G., Padrini R., Zordan R., Orlando R., Gallimberti L., Gessa G.L., Ferrara S.D. (1993), “Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers”, European Journal of Clinical Pharmacology, 45: 353-356.
  92. Sewell R.A., Petrakis I.L. (2011), “Does gamma-hydroxybutyrate (GHB) have a role in the treatment of alcoholism?”, Alcohol and Alcoholism, 46: 1-2.
  93. Skala K., Caputo F., Mirijello A., Vassallo G. Antonelli M., Ferrulli A., Walter H., Lesch O.M., Addolorato G. (2014), “Sodium oxybate in the treatment of alcohol dependance: from the alcohol withdrawal syndrome to the alcohol relapse prevention”, Export Opinion on Pharmacotherapy, 15: 245-257.
  94. Snead O.C., Gibson K.M. (2005), “Gamma-hydroxybutyric acid”, New England Journal of Medicine, 352: 2721-2732.
  95. Spielberger C.D., Gorsuch R.L., Lushenne R.E. (1970) Manual for the State – Trait Anxiety Inventory (Self-Evaluation Questionaire), Consulting Psychologists Press, Palo Alto.
  96. Stella L., Addolorato G., Rinaldi B., Capuano A., Berrino L., Rossi F., Maione S. (2008), “An open randomized study of the treatment of escitalopram alone and combined with γ-hydroxybutyric acid and naltrexone in alcohilc patients”, Pharmacological Research, 57: 312-317.
  97. Sullivan J.T., Sykora K., Schneiderman J., Naranjo C.A., Sellers E.M. (1989), “Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar)”, British Journal of Addiction, 84: 1353-1357.
  98. Tunnicliff G., Raess B.U. (2002), “Gamma-hydroxybutyratre (orphan medical)”, Current Opinion in Invetstigational Drugs, 3: 278-283.
  99. Veltrup C. (1994), “Assessment of craving in alcohol-dependent patients by means of a newly-developed questionnaire (Lübeck Craving-Recurrence Risk Questionnaire/Lübecker Craving-Risiko-Rückfall-Fragebogen)”, Wiener Klinische Wochenschrift, 106: 75-79.
  100. Verheul R., Van Den Brink W., Geerlings P. (1999), “A three-pathway psychological model of craving for alcohol”, Alcohol and Alcoholism, 34: 197-222.
  101. Vignoli T. (2013), “L’associazione di più farmaci per il trattamento dell’alcoldipendenza”, Mission, 37: 42-47.
  102. Wong G.T., Gibson K.M., Snead O.C. (2004), “From the street to the brain: neurobiology of the recreational drug-gamma-hydroxybutyric acid”, Trends in Pharmacological Sciences, 25: 29-34.
  103. Zung W.W.K. (1965), “A self-rating depression Scale”, Archives of General Psychiatry,12: 63-70.
  104. Zung W.W.K. (1972) “The Depression Status Inventory: an adjunct to the Self-rating Depression Scale”, Journal of Clinical Psychology, 28: 539-543.

Metrics

Metrics Loading ...